{"id":"teneligliptin-placebo-oral-tablet","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Injection site reaction"},{"rate":"1-5%","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting DPP-4, teneligliptin reduces the breakdown of incretin hormones, leading to increased insulin secretion in response to meals and decreased glucagon secretion. This results in improved glycemic control and reduced glucose production in the liver.","oneSentence":"Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:00.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT02916706","phase":"PHASE3","title":"Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-09","conditions":"Type 2 Diabetes Mellitus","enrollment":254},{"nctId":"NCT02924064","phase":"PHASE3","title":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-09","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204},{"nctId":"NCT00628212","phase":"PHASE2","title":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT00998881","phase":"PHASE3","title":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT02081599","phase":"PHASE4","title":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-01","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT05504226","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-10-12","conditions":"Type 2 Diabetes","enrollment":214},{"nctId":"NCT05504239","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-09-27","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT03508323","phase":"PHASE4","title":"Tenelia Elderly CGMS Study(TEDDY)","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2018-04-03","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT04446026","phase":"PHASE4","title":"A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-07-08","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT01805830","phase":"PHASE3","title":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT01798238","phase":"PHASE3","title":"Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-11","conditions":"Type 2 Diabetes Mellitus","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Teneligliptin Placebo Oral Tablet","genericName":"Teneligliptin Placebo Oral Tablet","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}